Atul Ramachandran, MD
Cardiovascular Disease · Omaha, NENPI 1811075773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $520 and has fallen 61.1% since, to $202 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NE, where the typical reported total is $1,663.
Across 91 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$408
- Amgen$256
- E.r. Squibb & Sons, L.L.C.$216
- Edwards Lifesciences$153
- Johnson & Johnson$138
- Boehringer Ingelheim$114
- plus $506 from 13 others
What the payments were for
- Food & beverage$1,792100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 21 | $408 |
| Amgen | 14 | $256 |
| E.r. Squibb & Sons, L.L.C. | 5 | $216 |
| Edwards Lifesciences | 1 | $153 |
| Johnson & Johnson | 9 | $138 |
| Boehringer Ingelheim | 7 | $114 |
| Merck | 7 | $106 |
| Novartis | 7 | $105 |
| Amarin Pharma, Inc. | 4 | $60 |
| AstraZeneca | 3 | $42 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Lundbeck LLC | 2 | $27 |
| Abbott | 2 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$144
How this compares
$1,792 in reported general payments places this provider in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $181,839 |
| XareltoRivaroxaban | 77 | $69,688 |
| VascepaIcosapent Ethyl | 11 | $7,922 |
| Metoprolol Succinate | 323 | $3,878 |
| BystolicNebivolol Hcl | 13 | $2,288 |
| Atorvastatin Calcium | 215 | $1,750 |
| Ezetimibe | 90 | $1,423 |
| Flecainide Acetate | 30 | $1,350 |
| Potassium Chloride | 80 | $1,326 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 56 | $1,289 |
| Carvedilol | 146 | $866 |
| Amiodarone Hcl | 65 | $733 |
| Rosuvastatin Calcium | 109 | $708 |
| Spironolactone | 141 | $682 |
| ClopidogrelClopidogrel Bisulfate | 51 | $614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $408 | $181,839153 claims |
| Johnson & JohnsonXarelto | $138 | $69,68877 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $13 | $2,28813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.